Charles River Laboratories International, Inc. $CRL Shares Sold by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 69.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,700 shares of the medical research company’s stock after selling 3,800 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Charles River Laboratories International were worth $266,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Cromwell Holdings LLC raised its holdings in shares of Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after acquiring an additional 152 shares during the last quarter. Neo Ivy Capital Management purchased a new stake in Charles River Laboratories International during the 2nd quarter worth about $29,000. Geneos Wealth Management Inc. raised its stake in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Allworth Financial LP lifted its holdings in Charles River Laboratories International by 172.7% in the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares in the last quarter. Finally, SJS Investment Consulting Inc. acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $48,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of analyst reports. Robert W. Baird set a $224.00 price objective on shares of Charles River Laboratories International in a research report on Friday. Wall Street Zen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Barclays raised their price objective on Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus price target of $203.07.

Charles River Laboratories International Trading Up 0.1%

Shares of CRL opened at $219.01 on Wednesday. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88. The firm has a market capitalization of $10.78 billion, a P/E ratio of -140.39, a price-to-earnings-growth ratio of 6.54 and a beta of 1.61. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The stock’s fifty day simple moving average is $188.76 and its 200 day simple moving average is $172.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping the consensus estimate of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The firm’s revenue was down .5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.59 earnings per share. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.